A new paradigm of age management: from masking the problem to targeting the root cause of aging
03.11.2026
Corporate
For investors
Medicines
Industry development
International focus
03.11.2026
Registration opens up the possibility for further launch of the drug on the market. This will provide specialists and patients with a modern therapeutic solution for managing metabolic health. Azerbaijan is a strategic destination for PROMOMED. In this regard, obtaining a registration certificate lays the foundations for the Company's long-term presence in the country.
The biopharmaceutical company PROMOMED is consistently working to expand the geographical presence of its own innovative drugs. The full production cycle, from the substance to the finished dosage form, ensures stable supply and cost predictability of the product. In the treatment of obesity and type 2 diabetes, the availability of a drug during the entire treatment period is of particular importance. The need for such therapy remains at a high level in Azerbaijan.
According to assessment According to the International Diabetes Federation, about 715,000 adults in the country live with diabetes, while about one in three does not know about their diagnosis. Data The National Strategy for the Prevention of Noncommunicable Diseases indicates a significant prevalence of overweight and obesity: overweight was recorded in 35.8% of the adult population, obesity — in 21.9%. Collectively, these indicators cover more than half of the country's adult citizens.
"Obesity and type 2 diabetes are major challenges for the healthcare system. Access to modern therapeutic solutions provides an opportunity for both the professional community and patients to turn the tide in the fight against excess weight. Correction of metabolic health leads to an improvement in the cardiovascular profile and a reduction in chronic inflammation. Ultimately, our goal is to help people maintain their health, quality of life, and the opportunity to stay active for as long as possible."
Azerbaijan has become the sixth country to register the drug Tirzetta®.1. Previously, PROMOMED received registration certificates for the drug in Russia, Belarus, Kazakhstan, Kyrgyzstan and Uzbekistan. At the same time, the Company has registered the first drug based on tirzepatide in Russia, Belarus, Kazakhstan and Kyrgyzstan.
Entering the South Caucasus market is a logical continuation of the strategy to expand the availability of modern therapy for obesity and type 2 diabetes in the post—Soviet countries. This step is a systematic movement towards export promotion to the markets of non-CIS countries._______________________________________
1. This drug is a prescription drug and should only be purchased as prescribed by a doctor. The drug has contraindications. Please read the instructions for use. Do not use the drug unless it has been prescribed to you by your doctor. When using the drug, always follow the instructions for use and the recommendations of your doctor.
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
